Abstracts tagged "rheumatoid arthritis"

Abstract Number: 61 • 2017 ACR/ARHP Annual Meeting
Resolution of Systemic Joint Inflammatory Processes and Regeneration of Existing Bone Damage upon TNF Blockade As Monitored By In Vivo Multimodal PET-CT Imaging in Progressed Experimental Arthritis
Silvia Hayer¹, Markus Zeilinger^2,3, Volker Weiss^3,4, Markus Seibt⁵, Birgit Niederreiter¹, Tetyana Shvets⁶, Monika Dumanic⁶, Florian Pichler⁶, Marcus Hacker⁶, Josef S. Smolen⁷, Kurt Redlich⁸ and Markus Mitterhauser⁶, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Faulty of Engineering, University of Applied Sciences, Winer Neustadt, Austria, ³Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁴Faculty of Engineering, University of Applied Sciences, Wiener Neustadt, Austria, ⁵Department Internal Medicine III, Division Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶Medical University of Vienna, Vienna, Austria, ⁷Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁸Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: To use in vivo multimodal [18F]FDG (fluoro-D-glucose, tracer for inflammation) and [18F]Sodium Fluoride (bone tracer) positron emission tomography/computed tomography (PET-CT) imaging for the monitoring…
Abstract Number: 2869 • 2017 ACR/ARHP Annual Meeting
Significant Decrease of T-Cells but Not Macrophages in the Synovium of Patients with Active Rheumatoid Arthritis after Treatment with Tocilizumab
Katerina Chatzidionysiou¹, Marianne Engström¹, Erik af Klint¹, Aase Hensvold¹ and Anca I Catrina², ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Tocilizumab (TCZ) is an anti-IL6R monoclonal antibody approved for the treatment of Rheumatoid Arthritis (RA). There is limited data on synovial tissue histology changes.…
Abstract Number: 171 • 2017 ACR/ARHP Annual Meeting
Finding Transcriptional Regulators Central to RA with Transcriptomics of IL17 Dose Response, Time Series, and siRNA Silencing in Stromal Cells
Kamil Slowikowski¹, Hung Nguyen², Gerald Watts², Fumitaka Mizoguchi³, Erika H. Noss⁴, Michael Brenner⁵ and Soumya Raychaudhuri⁶, ¹Harvard University, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁴Division of Rheumatology, University of Washington, Seattle, WA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is characterized by immune cell infiltration into the synovial membrane of the joint, where they engage stromal cells such as synovial…
Abstract Number: 2913 • 2017 ACR/ARHP Annual Meeting
the Periodontal Pathogen Aggregatibacter Actinomycetemcomitans Is Associated with Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis
Jon T. Giles¹, Jesper Reinholdt², Joan Bathon³, Felipe Andrade⁴ and Maximilian F. Konig⁵, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The oral pathogen Aggregatibacter actinomycetemcomitans (Aa) generates citrullinated proteins targeted by autoantibodies in RA through its pore-forming toxin leukotoxin A (LtxA). Aa-derived LtxA is…
Abstract Number: 394 • 2017 ACR/ARHP Annual Meeting
Female Tumor Necrosis Factor Transgenic Mice Have More Severe Arthritis Than Males and Supporessed Levels of Bifidobacterium Pseudolongum in Their Gut Microbiome
Emily Wu¹, Richard Bell², Alex Grier³, Steven Gill⁴, Edward Schwarz⁵ and Homaira Rahimi⁶, ¹Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, ²Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ³Rochester Genomics Center, University of Rochester, Rochester, NY, ⁴Genomics Research Center, University of Rochester, Rochester, NY, ⁵Orthopedeatrics, University of Rochester, Rochester, NY, ⁶Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Rheumatoid arthritis (RA) has an increased prevalence and severity in women compared to men, yet the underlying etiology of this sexual dimorphism is unknown.…
Abstract Number: 2963 • 2017 ACR/ARHP Annual Meeting
Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial
Bidisha Dasgupta¹, Kristen Sweet¹, Dick DeVries², Benjamin Hsu¹, Ian Gourley¹, Matthew Loza¹ and Peter C. Taylor³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Biologics Europe, Leiden, Netherlands, ³Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Ultrasound (US) is an established non-invasive tool for sensitively assessing disease activity at the individual‐joint level in rheumatoid arthritis (RA). Synovial thickness is detectable…
Abstract Number: 395 • 2017 ACR/ARHP Annual Meeting
Pharmacological and Safety Profiles of Cyclin-Dependent Kinase 4/6 Inhibitor, Candidate for Development As Rheumatoid Arthritis Therapeutic Option
Johji Nomura¹, Shunsuke Tsujimoto², Kei Tamura², Wataru Yamamoto², Hiroshi Takahashi², Kyohei Horie², Toshiya Mashiko², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is characterized by the infiltration of immune cells into the synovial tissues and the excessive proliferation of synovial…
Abstract Number: 396 • 2017 ACR/ARHP Annual Meeting
Phospho-STAT1 Inhibition Is the Initial Step after Tofacitinib Treatment in Rabbits with Severe Chronic Synovitis
Sandra Pérez-Baos, Paula Gratal, Juan Ignacio Barrasa, Ana Lamuedra, Gabriel Herrero-Beaumont and Raquel Largo, Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Tofacitinib (TOFA) is a Janus Kinase (Jak) inhibitor approved for the treatment of rheumatoid arthritis (RA) 1. It has recently been shown to selectively…
Abstract Number: 398 • 2017 ACR/ARHP Annual Meeting
An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis
Jing Yan¹, Nitin Joshi², Seth Levy², Sachin Bhagchandani², Kai Slaughter², Nicholas Sherman¹, Julian Amirault², Xueyin He², Tan Shi Rui², Michael Valic², Praveen Vemula³, Oscar Miranda², Oren Levy², Antonios Aliprantis⁴, Joerg Ermann¹ and Jeffrey Karp², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, India, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Many types of inflammatory arthritis (IA) are treated with systemic therapy. In situations where only one or a few joints are active, intra-articular drug…
Abstract Number: 417 • 2017 ACR/ARHP Annual Meeting
Improvement in Overall Work Productivity Among Biologic-NaïVe Patients with Rheumatoid Arthritis Treated with Tocilizumab Subcutaneous Injection: A Prospective, Real World, Observational Study in Japan
Yoshiya Tanaka¹, Hideto Kameda², Kazuyoshi Saito³, Yuko Kaneko⁴, Eiichi Tanaka⁵, Shinsuke Yasuda⁶, Naoto Tamura⁷, Keishi Fujio⁸, Takao Fujii⁹, Toshihisa Kojima¹⁰, Tatsuhiko Anzai¹¹, Chikuma Hamada¹², Yoshihisa Fujino¹³, Shinya Matsuda¹³ and Hitoshi Kohsaka¹⁴, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan, ³Tobata General Hospital, Fukuoka, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ⁷Department of Internal Medicine and Rheumatology, Juntedo University School of Medicine, Tokyo, Japan, ⁸Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ⁹Department of Rheumatism and Collagen Disease, Wakayama Medical University, Wakayama, Japan, ¹⁰Nagoya Univ. Grad. Schl. of Med., Nagoya, Japan, ¹¹Data Science Division, Statistics Analysis Department 1, EPS Corporation, Tokyo, Japan, ¹²Department of Information and Computer Technology, Tokyo University of Science, Tokyo, Japan, ¹³Department of Preventive Medicine and Community Health, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: This is the first study assessing the effect of subcutaneous tocilizumab (TCZ-SC) and/or conventional synthetic DMARDs (csDMARDs) on work productivity and activity impairment (WPAI)…
Abstract Number: 536 • 2017 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort
Ruediger Mueller¹, Frederik Mattow², Florian Popp³ and Johannes von Kempis⁴, ¹Division of Rheumatology, Cantonal Hospital, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Rorschacherstrasse 95, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Efficacy and safety of tofacitinib have been shown in several clinical studies. The…
Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Hirotaka Yamada², Yoshihide Ichise², Ikuko Naka³, Yo Ueda², Takaichi Okano², Soshi Takahashi⁴, Kengo Akashi⁵, Akira Onishi⁶ and Akio Morinobu⁴, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…
Abstract Number: 1326 • 2017 ACR/ARHP Annual Meeting
Alpha-Glucosidase Inhibitors Alter Gut Microbiota and Ameliorate Collagen-Induced Arthritis
Lingshu Zhang^1,2, Pingfang Song², Xiaowei Zhang², Christina Metea², Matthew Schleisman², Lisa Karstens², Eric Leung², Jun Zhang³, Qiang Xu^2,4, Yi Liu⁵, Mark Asquith² and Cong-Qiu Chu^6,7, ¹Department of Rheumatology, West China Hospital, Sichuan University, Chengdu, China, ²Oregon Health & Science University, Portland, OR, ³MD Anderson Cancer Center, Houston, TX, ⁴Guangzhou University of Chinese Medicine, Guangzhou, China, ⁵Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, ⁶Rheumatology, Oregon Health & Science University, Portland, OR, ⁷Rheumatology, VA Portland Health Care System, Portland, OR
Background/Purpose: Acarbose, an alpha-glucosidase inhibitor anti-diabetic drug exhibited anti-arthritic effects. The mechanism that acarbose exerts its anti-arthritic effects is not fully understood. Since > 90%…
Abstract Number: 1331 • 2017 ACR/ARHP Annual Meeting
A Pathogenic Role of Porphyomonas Gingivalis Fimbriae (FimA) in Periodontitis-Associated Rheumatoid Arthritis
Ji-Won Kim¹, Jennifer Lee², Yeon-Sik Hong³, Sung-Hwan Park² and Ji Hyeon Ju², ¹Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Periodontitis induced by oral pathogen Porphyromonas gingivalis (Pg) has been suggested to be associated with rheumatoid arthritis (RA). Pg peptidyl arginine deiminase -mediated citrullination…
Abstract Number: 460 • 2016 ACR/ARHP Annual Meeting
TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models
Yohei Yoshiga¹, Fumihito Hosoi¹, Satoru Iguchi¹, Ryuusuke Kaneko¹, Yoshinori Nakachi¹, Daichi Akasaka¹, Kenji Tanaka², Kazuhiko Yonekura², Teruhiro Utsugi², Eiji Sasaki² and Yoshikazu Iwasawa², ¹TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, ²TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
Background/Purpose: Bruton’s Tyrosine Kinase (BTK), a non-receptor tyrosine kinase is involved in intracellular signaling pathways downstream of several receptors, including the B cell receptor (BCR),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].